Consolidation reduced dose whole brain radiotherapy (rdWBRT) following methotrexate, rituximab, procarbazine, vincristine, cytarabine (R-MPV-A) for newly diagnosed primary CNS lymphoma (PCNSL): Final results and long-term outcome

Reporter: Annemarie Fernandes
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 3 de junio del 2012

Translation for this article does not exist


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

ASCO Updates Guidelines for Colony-Stimulating Factor Use

Jul 15, 2015

Special article updates 2006 guidelines, including addition of tbo-filgrastim and filgrastim-sndz

Chromosomal Abnormalities Signal CNS Involvement in AML

Dec 29, 2011

Further study needed to establish role of cytogenetics in predicting CNS disease in AML

Exposure to Tamoxifen Causes CNS Cell Death

Sep 20, 2013

MEK1/2 inhibition rescues glial progenitor cells from toxicity; prevents tamoxifen-induced cell death

From the National Cancer Institute